Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis.

about

Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis.

Item

http://www.wikidata.org/entity/Q49596689

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Efficacy and safety of the ada ...... -to-severe ulcerative colitis.

@en

Efficacy and safety of the ada ...... -to-severe ulcerative colitis.

@nl

type

Item

label

Efficacy and safety of the ada ...... -to-severe ulcerative colitis.

@en

Efficacy and safety of the ada ...... -to-severe ulcerative colitis.

@nl

prefLabel

Efficacy and safety of the ada ...... -to-severe ulcerative colitis.

@en

Efficacy and safety of the ada ...... -to-severe ulcerative colitis.

@nl

P1476

Efficacy and safety of the ada ...... -to-severe ulcerative colitis.

@en

P2093

Ajit Sood

http://www.w3.org/2001/XMLSchema#string

Arshdeep Singh

http://www.w3.org/2001/XMLSchema#string

Kirandeep Kaur

http://www.w3.org/2001/XMLSchema#string

Ramit Mahajan

http://www.w3.org/2001/XMLSchema#string

Vandana Midha

http://www.w3.org/2001/XMLSchema#string

Varun Mehta

http://www.w3.org/2001/XMLSchema#string

Vikram Narang

http://www.w3.org/2001/XMLSchema#string

P2860

Current status of biosimilars in the treatment of inflammatory bowel diseases

Infliximab for induction and maintenance therapy for ulcerative colitis

Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study.

Predicting outcome in severe ulcerative colitis.

Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab.

Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort.

Biological agents for ulcerative colitis: hypes and hopes.

A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis.

Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series.

Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.

P304

83-89

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5217/IR.2018.16.1.83

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29422802

http://www.w3.org/2001/XMLSchema#string

P921

adalimumab

P932

5797276

http://www.w3.org/2001/XMLSchema#string